Rafferty Asset Management
DSGN icon

Rafferty Asset Management’s Design Therapeutics DSGN Stock Holding History

Rafferty Asset Management’s Portfolio DSGN Stock Details DSGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-243,585
Closed -$2.5M – 1149
2022
Q4 		$2.5M Buy
243,585
+212,534
+684% +$2.88M 0.02% 517
2022
Q3 		$519K Buy
+31,051
New +$618K 0.01% 843

Other funds holding DSGN

SOCM
SR One Capital Management Wayne, Pennsylvania $915M AUM 209.71% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
LGM
Logos Global Management San Francisco, California $2B AUM 444.09% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Rafferty Asset Management's DSGN Position: Q1 2023 in Review

Rafferty Asset Management sold out of Design Therapeutics (DSGN) in Q1 2023, closing a stake of 243,585 shares — an estimated $2.5M sold.

Rafferty Asset Management first reported a position in DSGN in Q3 2022 and held it in 2 quarters. The position peaked at $2.5M in Q4 2022. 96 funds tracked by Wall St. Rank hold DSGN as of Q1 2023.

  • Rafferty Asset Management reported no remaining Design Therapeutics position as of Q1 2023 after selling out during the quarter.
  • Rafferty Asset Management sold 243,585 Design Therapeutics shares in Q1 2023, an estimated $2.5M.
  • Rafferty Asset Management first reported a position in Design Therapeutics in Q3 2022 and held it in 2 quarters.
  • Rafferty Asset Management's Design Therapeutics position peaked at $2.5M in Q4 2022.
  • 96 funds tracked by Wall St. Rank held Design Therapeutics as of Q1 2023.

Based on Rafferty Asset Management's 13F filing for Q1 2023, filed 11 May 2023.